-
TScan Therapeutics NASDAQ:TCRX TScan is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company’s lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. The company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Location: | Website: www.tscan.com | Industry: Research and Development in Biotechnology | Sector: Professional, Scientific, and Technical Services
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
82.1M
Cash
297.7M
Avg Qtr Burn
-17.81M
Short % of Float
5.32%
Insider Ownership
0.88%
Institutional Own.
99.46%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
TSC-203-A0201 Details Cancer, Solid tumor/s | Phase 1 Data readout | |
TSC-100 & TSC-101 Details Cancer, Hematologic malignancies | Phase 1 Data readout | |
TSC-203-A0201, TSC-200-A0201, TSC-204-A0201, TSC-204-C0702,TSC-201-B0702, TSC-204-A0101 Details Cancer, Solid tumor/s, Human papillomavirus | Phase 1 Data readout |